Navigation Links
Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
Date:11/3/2010

BASKING RIDGE, N.J., Nov. 3, 2010 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will be presenting at IMPACT 2010 held at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.  Ms. McDonald's presentation will be given at 11:13 a.m. EST on Wednesday, November 10 in the Life Science Room #106AB and will include an overview of the Company's pipeline with emphasis on the lead development program, the innovative anticoagulant system, REG1.  As the oldest and most established venture conference in the Northeast, IMPACT 2010 continues to offer topical speakers, relevant panel sessions, cutting-edge company presentations, unparalleled networking and visibility opportunities for both attendees and sponsors alike.

ABOUT REGADO BIOSCIENCESRegado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its complementary active control agent (anivamersen, a.k.a. RB007).  Anivamersen can be used to selectively completely or partially reverse the anticoagulant effect of pegnivacogin.  REG1, presently in a phase 2b clinical trial (the RADAR trial), is intended for application in arterial thrombosis applications, initially in Acute Coronary Syndrome patients intended for Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 recently completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial in 2011.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a specific GPVI inhibitor and its active control agent (RB571 and RB515, respectively).  REG3 is planned to enter phase 1 human clinical testing in 2011 and will be indicated for antiplatelet therapy.  Information pertaining to Regado's clinical programs may be obtained at www.clinicaltrials.gov.

ABOUT APTAMERSPegnivacogin is a member of a class of compounds called aptamers.  Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein.  A key unique feature of aptamers derives from the fact that they are formed from nucleic acids.  As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing its biologic effects.  Anivamersen is the active control agent of pegnivacogin.  

More information can be found at www.regadobio.comContact:  Ellen McDonald, Chief Business Officer, Regado Biosciences, 1-908-580-2113, emcdonald@regadobio.comMedia Contact:Tiberend Strategic Advisors, Inc.1-212-827-0020Andrew Mielach, amielach@tiberendstrategicadvisors.com
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
2. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
3. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
4. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
5. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
6. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
7. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
8. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
9. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
10. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016  The Addiction Treatment Advisory ... of Managed Care Pharmacy (AMCP), has released detailed ... address the opioid addiction crisis, including through improved ... ATAG,s newly released paper, "The Role ... Naloxone," addresses many issues around gaps and barriers ...
(Date:12/2/2016)... 2016 CVS Health Corporation (NYSE: ... York City on Thursday, December 15, 2016, beginning at 8:00 a.m. (ET). ... provide an in-depth review of the company,s strategies to ... will also discuss 2017 earnings guidance during the event. ... event will be broadcast simultaneously on the Investor Relations ...
(Date:12/2/2016)... 2, 2016   CytoSorbents Corporation (NASDAQ: ... European Union approved CytoSorb ® cytokine adsorber to ... worldwide, announced that Dr. Phillip Chan , Chief ... LD Micro Main Event investor conference held from ... Luxe Sunset Boulevard Hotel in Los Angeles, ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs ... properties including its unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) ... Nothing Water has been available in several ShopRite and FoodTown stores in NJ and ...
(Date:12/2/2016)... Abilene, Texas (PRWEB) , ... December 02, 2016 , ... ... article that delves into how this current generation fits into Bible Prophecy. Yisrayl says ... lists various facts pointing to this conclusion, showing how the details line up exactly ...
(Date:12/2/2016)... Francisco, CA (PRWEB) , ... December 02, 2016 ... ... digitally-enabled care journeys, announced today that it has raised $6.0 million in an ... inspired by Clarify Health’s conviction that patients and their caregivers can receive far ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today CloudMine, a secure, ... was named the best Sales Team of 2016 as part of the 2016 ... by the Software & Information Industry Association (SIIA), the principal trade association for ...
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for ... $1,000 each from the National Family Partnership and the Drug Enforcement Administration as part ... their homes and the 10 winning schools who decorated their campuses with this year’s ...
Breaking Medicine News(10 mins):